SGRY · Surgery Partners, Inc.
$13.87
-0.54 (-3.75%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.89B
Shares
130.92M
Volume · Sep 30
1.86M
Avg daily vol (3M)
2.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.87
Open$14.32
Day$13.86–14.42
52W close$11.49–22.94
Avg vol 30d2.6M
Short int13.3M · 10.2% float · 6.4d
Short vol60%
Last earningsAug 10, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 6 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.37B
Trailing 12 months
Net income (TTM)
−$88.60M
Trailing 12 months
Revenue growth YoY
+2.7%
Year over year
Operating margin
11.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
10.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
-34.2%
Trailing year
Short interest
10.2%
Latest settlement · 6.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−5%
below
RSI (14)
46
neutral
MACD trend
Positive
52-week position
21%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+7%
trailing
YTD return
−10%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$161.2K over 90 days · 0% sells
Short interest
Rising
10.15% of float · ▲ +2.6% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
190 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+54%
Y/Y
Free cash flow
$195.6M
Buyback
$200.0M
authorized
Balance sheet
$3.5B
net debt
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
2026
Revenues
$3.35B – $3.45B
prior FY $3.31B
midpoint +2.8% Y/Y
Adjusted EBITDA
Non-GAAP
at least $530M
2026 Full Year
Organic Adjusted EBITDA Growth
Non-GAAP
Initiated
at least 4.2%
Same-Facility Revenue Growth
Initiated
at least 3%
Third Quarter 2026
Adjusted EBITDA
Non-GAAP
Initiated
25.75% – 26.25%
Revenue
Initiated
25% – 25.5%
Guided vs delivered
· last 3 settled
Revenues
2024
guided at least $3.08B
$3.11B
In line
Revenue
full year 2023
guided $2.75B
$2.74B
Miss −0.2%
Revenue growth
full year 2021
guided $2.21B – $2.25B
$2.23B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−5%
Bearish
RSI (14)
46
Neutral
MACD trend
Positive
Bullish
52-week position
21%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$161.2K over 90 days · 0% sells
Short interest
Rising
10.15% of float · ▲ +2.6% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
190 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11
Now $14 · 21%
Range high $23
vs 200-day avg -5%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $227.5M | Six Months Ended June 30 | — |
| Adjusted EBITDA excluding Idaho Falls Market non-GAAP | $98.3M | Q2 2026 | — |
| Adjusted EBITDA margin non-GAAP | 13.7% | Six Months Ended June 30 | — |
| Adjusted EBITDA related to unconsolidated affiliates non-GAAP | $32.8M | Six Months Ended June 30, 2026 | — |
| Adjusted net income (loss) attributable to common stockholders non-GAAP | $9.4M | Six Months Ended June 30, 2026 | — |
| Adjusted net income per share attributable to common stockholders - Basic non-GAAP | $0.07 | Six Months Ended June 30, 2026 | — |
| Adjusted net income per share attributable to common stockholders - Diluted non-GAAP | $0.07 | Six Months Ended June 30, 2026 | — |
| Cases | 325,577 | Six Months Ended June 30 | — |
| Days adjusted same-facility revenues growth | 5% | the second quarter of 2026 filing | — |
| New Physician Recruits | 190 | Q2 2026 | — |
| Number of consolidated surgical facilities as of the end of period | 120 | Six Months Ended June 30 | — |
| Number of surgical facilities as of the end of period | 178 | Six Months Ended June 30 | — |
| Number of work days in the period | 127 | Six Months Ended June 30, 2026 | — |
| Revenue per case | $5,098 | Six Months Ended June 30 | — |
| Same-facility case growth | 0.8% | Six Months Ended June 30 | — |
| Same-facility Case growth (days adjusted) | 0.8% | Six Months Ended June 30, 2026 | — |
| Same-facility cases | 370,774 | Six Months Ended June 30 | — |
| same-facility cases growth | 0.3% | the second quarter of 2026 filing | — |
| Same-Facility Rate | 4.8% | Q2 2026 | — |
| Same-facility Revenue growth (days adjusted) | 4.9% | Six Months Ended June 30, 2026 | — |
| Same-facility revenue per case | $5,029 | Six Months Ended June 30 | — |
| Same-facility revenue per case growth | 4% | Six Months Ended June 30 | — |
| Same-Facility Surgical Cases Growth | 0.3% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGRY
this stock
Surgery Partners, Inc.
|
$1.89B | -10.2% | +19.3% | — | 10.2% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -11.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +28.6% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +14.5% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGRY | -4.7% | -5.0% | +7.2% | -0.1% | -10.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -4.1% | -5.1% | -5.0% | +0.4% | -22.1% |
Capital returns
Buyback program
· as of Feb 26, 2026
Authorized
$200.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.